Locomotor reactivity to a novel environment and sensitivity to MK-801 in five strains of mice

Behavioural Pharmacology
Mikhail KalinichevDeclan N C Jones

Abstract

The ability of a noncompetitive antagonist of the N-methyl-D-aspartate receptor, MK-801, to stimulate locomotor activity (LMA) in mice was compared across CD-1, MF1, NIH Swiss (NIHS), C57BL6/J and BALB/C strains with the aim of identifying the most suitable strain for a putative model of schizophrenia. Animals were habituated to novel LMA cages for 1 h before receiving either saline or MK-801 (0.1, 0.32, or 0.5 mg/kg; i.p.) and activity recorded for 2 h. At the end of the test, blood and brain samples were taken and the total concentrations of MK-801 determined. Mice strains differed in habituation; C57BL6/J mice were the most active, whereas BALB/C mice were the least active and slowest to habituate. Robust strain-dependent differences in sensitivity to MK-801 were found, but not to saline. NIHS, C57BL6/J and BALB/C were more active in response to MK-801, exhibiting more rapid, robust and long-lasting increases in LMA than CD-1 or MF1 mice. Total concentrations of MK-801 in the brain did not differ across the strains. We found no correlation between the LMA stimulated by novelty and MK-801. NIHS, C57BL6/J and BALB/C appeared significantly more sensitive to MK-801 than CD-1 and MF1 and can be strains of choice in evaluating the...Continue Reading

References

Feb 1, 1996·Physiology & Behavior·B C JonesM N Cook
Nov 22, 1997·European Journal of Pharmacology·P MartinM L Carlsson
Mar 4, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J D Jentsch, R H Roth
Mar 30, 1999·European Journal of Pharmacology·I Ninan, S K Kulkarni
Apr 21, 2001·Psychopharmacology·A HarkinB E Leonard
Nov 14, 2002·Behavioural Brain Research·J Adriaan Bouwknecht, Richard Paylor
Nov 14, 2002·Behavioural Brain Research·Xiangdong TangLarry D Sanford
Jul 5, 2003·Neuropharmacology·Ludovic LerichePierre Sokoloff
Aug 4, 2004·Psychopharmacology·Jinhua WuLei Yu
Sep 16, 2005·Psychopharmacology·Robert R FreedmanManuel E Tancer

❮ Previous
Next ❯

Citations

Nov 17, 2009·European Journal of Pharmacology·Alex V IarkovJeffrey N Joyce
Mar 13, 2012·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·P BercikE F Verdu
Aug 27, 2015·Journal of Agricultural and Food Chemistry·Xiaofei LiuXuewu Zhang
Nov 19, 2011·Journal of Neurogenetics·Brice CampoSylvain Celanire
Jan 7, 2011·The International Journal of Neuropsychopharmacology·Mikhail Kalinichev, Lee A Dawson
Apr 22, 2009·Behavioural Brain Research·Yavuz AyhanMikhail V Pletnikov
Oct 30, 2016·Biochemical and Biophysical Research Communications·Kaoru SeirikiHitoshi Hashimoto
Nov 4, 2011·Journal of Clinical and Experimental Neuropsychology·Christopher J O'HalloranElsdon Storey
Jan 7, 2020·Experimental Neurobiology·Darine Froy N MabungaSe Jin Jeon
Jul 1, 2017·Frontiers in Cellular Neuroscience·Marta Perez-RandoJuan Nacher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here